I n March this year, flgrastim-sndz became the frst biosimilar to receive approval from the US Food and Drug Administration for use in the United States. Biosimilars are biological products that show comparable quality, efcacy, and safety to a reference drug that is already approved. In this case, flgrastim-sndz, by Sandoz, a Novartis company, is a biosimilar of Amgen's flgrastim, the reference drug or originator, which is already licensed in the United States for 5 indications, including for cancer patients undergoing treatments that deplete white blood cells, as well as those preparing for autologous peripheral blood stem-cell transplant, or those with severe, chronic neutropenia. 1 Te launch of the biosimilar was delayed by a lawsuit by Amgen, but it was subsequently cleared for marketing after a US Court of Appeals ruled in July that flgrastim-sndz could be marketed after September 2, 2015. Te biosimilar licensure pathway is a product of the Biologics Price Competition and Innovation Act as part of an efort to encourage competition and promote lower drug prices (see sidebar, p. 421).
Te flgrastim drugs are granulocyte-colony stimulating factor (G-CSF) analogs that act to boost the release of white blood cells from the bone marrow. Approval of the biosimilar was based on data from 5 pharmacokinetic and pharmacodynamic studies, 5 nonclinical studies, and 2 clinical studies, which confrmed that there were no clinically meaningful diferences from the reference drug.
Overall, 20 lots of flgrastim-sndz drug product, 6 lots of EP2006 drug substance, and 10-15 lots of flgrastim were compared. Te functional and physicochemical properties, product-related substances, impurities, and stability profles were all highly similar. After treatment with a single dose of either flgrastim-sndz or flgrastim, pharmacokinetic and pharmacodynamic studies confrmed that the area under the curve and maximum concentration, the absolute neutrophil count (ANC), and CD34-positive cell counts were within 80%-125% of each other.
Te key clinical study was the nonrandomized, doubleblind, multicenter phase 3 PIONEER study that compared the efcacy and safety of flgrastim-sndz (Zarxio) and flgrastim (Neupogen) in breast cancer patients who were treated with myelosuppressive chemotherapy. 2 Eligible women aged 18 years or older, with histologically proven breast cancer, an Eastern Cooperative Oncology Group performance status of ≤2, and adequate bone marrow function, who were scheduled to receive neoadjuvant chemotherapy with docetaxel (75 mg/m 2 ), doxorubicin (50 mg/ m 2 ), and cyclophosphamide (500 mg/m 2 ) were randomized equally to 1 of 4 treatment arms. Randomization was strat- ifed by adjuvant or neoadjuvant chemotherapy.
What's new, what's important
Chemotherapy was administered intravenously on Day 1 of each cycle, every 3 weeks, for 6 cycles. Patients received reference flgrastim, the biosimilar flgrastim-sndz, or 1 of 2 alternating regimens, with the flgrastim drugs administered subcutaneously at 5 µg/kg body weight a day from Day 2 of each cycle until ANC recovered to 10 x 10 9 /L or for a maximum of 14 days.
Lab assessments were performed at screening, on Day 1 of each chemotherapy cycle, and at the end of treatment. Complete blood counts were assessed on Day 1 and then daily in Cycle 1 until ANC reached 10 x 10 9 /L or until Day 15, then in cycles 2-6 on Day 1, Day 7, and daily thereafter. Body temperature was recorded on days 1-21 of each cycle and at the end of treatment. Injection site reactions were monitored after each application and concomitant medications and adverse events (AEs) were assessed at every visit. Antirecombinant human G-CSF antibody formation was examined using radioimmunoprecipitation at Day 1 of each cycle, at the end of treatment, and at study end.
Te primary endpoint was duration of severe neutropenia, defned as the number of consecutive days from ANC <0.5 x 10 9 /L to ≥0.5 x 10 9 /L during Cycle 1 of chemotherapy. Among 218 patients who were randomized, with a
Mechanism of action G-CSF analog replenishes neutrophils
Granulocyte-colony stimulating factor (G-CSF) is a growth factor that acts on neutrophil progenitor cells in the bone marrow by binding to its receptor on the surface of these cells. Filgrastim-sndz is a biosimilar for the US-licensed flgrastim;
biosimilars are analogous to generics, but refer to biological products rather than small molecule drugs, and are not exactly the same as their reference product.
Before 2010, the only way to obtain FDA approval for a biosimilar was to go through the full new drug application process. The Biologics Price Competition and Innovation Act, signed into law in March 2010, created an abbreviated licensure pathway to accommodate biological products, enabling regulatory approval for those that could be shown to be "biosimilar" or "interchangeable" with an FDA-licensed reference product, by permitting approval without the requirement for a full complement of preclinical and clinical data. Filgrastim-sndz was the frst biosimilar to be approved in the United States via this pathway.
Biosimilar flgrastim-sndz is a G-CSF analog which helps to combat neutropenia and boost white blood cell production via binding to the G-CSF receptor on the surface of neutrophil precursors found in the bone marrow. Subsequent activation of intracellular signaling pathways leads to transcription of genes that regulate neutrophil differentiation, maturation, and proliferation.
Community Translations
median age of 50 years, median duration since breast cancer diagnosis of 1 month, and with predominantly stage II/ III disease, the mean duration of severe neutropenia was 1.17 days for the biosimilar, compared with 1.20 days for the reference product.
Secondary endpoints included the number of patients reporting 1 or more fever episodes, total number of days of fever, incidence of febrile neutropenia (FN), and hospitalization owing to FN. In the frst cycle, fever episodes occurred in 6.6% of patients in the biosimilar arm, compared with 2.8% in the reference arms, most of which resolved on the same day, with a maximum duration of 2 days in both arms. One or more episodes of FN were reported in 4.7% and 1.9% patients, respectively, and led to hospitalization in 0.9% patients in each arm.
Over all cycles, the rate of fever episodes was 15% and 4.3% for the biosimilar and reference arms, respectively, with a maximum duration of 2 days in both arms. Five percent of patients reported 1 or more episodes of FN in the biosimilar arm, and all of them were hospitalized, compared with no episodes in the reference arm.
Comparing alternating with nonalternating regimens, fever episodes occurred at a rate of 13.5% and 9.3%, respectively, with a maximum duration of fever of 2 days, compared with 9 days. In the alternating arm, 6.7% of patients experienced 1 or more episodes of FN, compared with 2.3% in the nonalternating arm, leading to hospitalization in 1.1% and 2.3% of patients, respectively. Te depth of ANC nadir was similar across all arms, in the frst cycle and subsequent cycles.
None of the patients in the study developed binding or neutralizing antibodies against G-CSF. Treatment-emergent AEs occurred in 20.6% patients in the biosimilar arm, compared with 19.6% patients in the reference arm in Cycle 1. One patient in the biosimilar arm died from pulmonary embolism, but there was no suspected relationship to the drug. Serious AEs included FN, anemia, leukopenia, diarrhea, pulmonary embolism, and hypertensive crisis. Injection site reactions were rare and mild/moderate in intensity.
Dosing of flgrastim-sndz depends on the indication. In patients with cancer who receive myelosuppressive chemotherapy, the starting dose is 5 µg/kg a day as a subcutaneous injection, short intravenous infusion, or continuous IV infusion; in those undergoing bone marrow transplantation, the dose is 10 µg/kg a day as an IV infusion for no longer than 24 hours; in patients undergoing autologous peripheral blood progenitor cell collection and therapy, the dose is 10 µg/kg a day as a subcutaneous injection for at least 4 days before the frst leukapharesis, continued until the last leukapharesis; patients with congenital neutropenia receive a 6-µg/kg subcutaneous injection twice daily; and patients with cyclic/idiopathic neutropenia receive a 5-µg/ kg subcutaneous injection daily.
Filgrastim-sndz is contraindicated in patients with a history of serious allergic reactions, included anaphylaxis, to human G-CSF. Te prescribing information provides further details on the risk of allergic reactions, in addition to other warnings and precautions regarding splenic rupture, acute respiratory distress syndrome, sickle cell crisis, glomerulonephritis, alveolar hemorrhage and hemoptysis, capillary leak syndrome, myelodysplastic syndrome and acute myeloid leukemia, cutaneous vasculitis, thrombocytopenia, leukocytosis, potential efects on tumor cells, and transient positive bone-imaging changes. 3 
